Page 33 - GlaxoSmithKline Pharmaceuticals AR 2012
Basic HTML Version
29
Environment:
We are implementing an environmental sustainability strategy across our entire value chain – from
raw materials to product disposal. The strategy focuses on carbon dioxide and other emissions that
contribute to climate change, water use, waste reduction, and environmental stewardship – which
covers the other impacts of our materials and products.
Our policy on environment conforms to local laws as well as GSK’s global standards. Various initiatives
for energy efficiency and renewable energy were undertaken at our Nashik site.
•
The site has achieved 7% reduction in specific energy consumption and carbon footprint
(Gigajoules / million pack) compared to 2011.
•
Installation of a variable frequency drive of 1000KW on the air compressor has helped to
reduce the power consumption by 50000Kwh / Year
•
The site is working on specific initiatives to reduce the consumption of fossil fuels as well as
carbon footprint. A specific project has been initiated to modify the existing boiler operations
by using briquettes (bagasse). This will reduce the CO
2
emissions by 1500 tons / year. The
project is expected to be completed in 2013.
•
Continued efforts for monitoring of noise levels, recycling of waste and monitoring of gaseous
emissions from the boiler have helped sustain a high level of energy efficiency.
•
Solar hot water systems for use in canteen.
The emissions generated by the Company are within limit specified by Maharashtra Pollution Control
Board. No show cause notice or warning letter issued by Maharashtra Pollution Control Board.
With regard to waste management, our waste is segregated and given to authorized vendors for
recycling wherever appropriate. Treated site affluent is used for site gardening. Site has zero discharge
of ETP.
We publish our positions online including:
•
Climate change
•
The impact of climate change on health
•
Genetically modified micro-organisms and EHS
•
Pharmaceuticals in the environment
•
Ozone depletion and metered-dose inhalers for asthma
•
Ozone depleting substances in plant and equipment
Public policy and patient advocacy:
GSK is a member of various industrial and trade bodies like CII, Mumbai Chamber of Commerce, OPPI
and PHRMA. We are part of various task forces and forum within these chambers and work closely with
the industry bodies in devising strategies for improving healthcare in the country as well for providing
input into public policy with respect to the same.
Inclusive growth:
Our community development projects are focused in the area of facilitating healthcare, education and
sustainable livelihoods to the underserved and underprivileged targeting women, children and the
elderly as appropriate. The objective of these initiatives is to catalyse change and to improve service
levels in these areas. This is done through working with pre-screened NGOs.
The programmes we support are designed to have a long term, sustainable impact. We set ambitious
commitment and work with experienced partners.
We also encourage employees to get involved as volunteers through our Orange Day and PULSE
initiatives. Orange Day is a one day employee volunteering initiative while PULSE is a global
volunteering initiative which gives an employee a chance to spend 3 to 6 months of his time working
with an NGO.
For the year 2011, the Company’s net profit after tax was Rs. 430.60 crores and investment on social
commitment for the year 2012 was Rs. 2.78 crores or 0.64 percent of the Net Profit. Our product
donation (at cost) were Rs. 1.92 Lakhs.
